Blood Pressure Control in Type 2 Diabetes Mellitus
Authors: Mori J. Krantz
Journal: Annals of Internal Medicine (2004)

Letters16 March 2004Blood Pressure Control in Type 2 Diabetes MellitusMori J. Krantz, MDMori J. Krantz, MDFrom Denver Health's Cardiac Risk Reduction Program, Denver, CO 80204.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-140-6-200403160-00020 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In their clinical guideline addressing optimal antihypertensive therapy in patients with type 2 diabetes mellitus (1), Vijan and Hayward pointed out that effective treatment of hypertension is more important than tight glucose control in reducing vascular complications, which claim the lives of 80% of diabetic persons. However, in choosing an optimal agent, Vijan and Hayward made no clinical distinction between angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs).Patients with type 2 diabetes mellitus frequently experience acute myocardial infarction (MI) and subsequent congestive heart failure because of left ventricular systolic dysfunction. In large randomized trials of both ...References1. Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med. 2003;138:593-602. [PMID: 12667032] LinkGoogle Scholar2. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360:752-60. [PMID: 12241832] CrossrefMedlineGoogle Scholar3. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al . Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-7. [PMID: 10821361] CrossrefMedlineGoogle Scholar4. Berry C, Norrie J, McMurray JJ. Are angiotensin II receptor blockers more efficacious than placebo in heart failure? Implications of ELITE-2. Evaluation of Losartan In The Elderly [Editorial]. Am J Cardiol. 2001;87:606-7, A9. [PMID: 11230847] CrossrefMedlineGoogle Scholar5. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al . Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-906. [PMID: 14610160] CrossrefMedlineGoogle Scholar6. 2002 Drug Topics Redbook. Montvale, NJ: Thomson Medical Economics; 2002. Google Scholar Author, Article, and Disclosure InformationAffiliations: From Denver Health's Cardiac Risk Reduction Program, Denver, CO 80204. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoTreatment of Hypertension in Type 2 Diabetes Mellitus: Blood Pressure Goals, Choice of Agents, and Setting Priorities in Diabetes Care Sandeep Vijan and Rodney A. Hayward Blood Pressure Control in Type 2 Diabetes Mellitus Sandeep Vijan and Rodney A. Hayward Metrics 16 March 2004Volume 140, Issue 6Page: 487KeywordsACE inhibitorsAngiotensin receptor blockerGlucoseHeart failureHemodynamicsHypertensionRandomized trialsStable coronary artery diseaseTreatment guidelinesType 2 diabetes ePublished: 16 March 2004 Issue Published: 16 March 2004 CopyrightCopyright © 2004 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...